---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-25-000020"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-04-22T23:59:59+00:00"
generated_at: "2026-05-23T09:12:12.099004+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# iBio licenses first-in-class anti-Activin E antibody from AstralBio for up to $28M in milestones

## Summary
- Upfront $750K credit applied toward option fee; total milestone payments up to $28M, payable in cash or stock.
- Antibody demonstrated fat-selective weight loss and synergy with GLP-1 in obese rodent model.
- iBio also amended AstralBio collaboration to add a fifth cardiometabolic target using its AI platform.
- AstralBio eligible for low to mid-single-digit sublicense fees on any sublicense proceeds.
- iBio solely responsible for all development, manufacturing, and commercialization worldwide.

## SEC filing metadata
- accession: 0001420720-25-000020
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-04-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000020/0001420720-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000020/ibio-20250421x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-25-000020
- JSON: https://secwatch.observer/filing/0001420720-25-000020.json
- Plain text: https://secwatch.observer/filing/0001420720-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.